
Andreas H Scheel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7297466/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. Lung Cancer, 2022, 168, 10-20.	2.0	6
2	High-Throughput Profiling of Colorectal Cancer Liver Metastases Reveals Intra- and Inter-Patient Heterogeneity in the EGFR and WNT Pathways Associated with Clinical Outcome. Cancers, 2022, 14, 2084.	3.7	5
3	Screening of FGFR patients for FGFR directed clinical trials in Network Genomic Medicine (NGM): Real-world data Journal of Clinical Oncology, 2022, 40, e21013-e21013.	1.6	0
4	Optimized PD-L1 scoring of gastric cancer. Gastric Cancer, 2021, 24, 1115-1122.	5.3	25
5	Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients. Surgical Oncology, 2021, 37, 101611.	1.6	2
6	High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. ERJ Open Research, 2021, 7, 00787-2020.	2.6	2
7	"Interchangeability―of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	5.5	135
8	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
9	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	1.1	178
10	Interlaboratory concordance of <scp>PD</scp> ‣1 immunohistochemistry for nonâ€smallâ€cell lung cancer. Histopathology, 2018, 72, 449-459.	2.9	71
11	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2
12	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
13	Physical basis of the â€~magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. Diagnostic Pathology, 2018, 13, 19.	2.0	15
14	Optimized expression-based microdissection of formalin-fixed lung cancer tissue. Laboratory Investigation, 2017, 97, 863-872.	3.7	3
15	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	12.4	55
16	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology, 2016, 29, 1165-1172.	5.5	340
17	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
18	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer, 2015, 15, 291.	2.6	7

#	Article	IF	CITATIONS
19	Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data. Modern Pathology, 2015, 28, 1528-1534.	5.5	47